UnknownNot Applicable

Suturing With U-Technique Versus Un-Reapproximated Wound Edges During Removal of Closed Thoracostomy Tube Drain

Nigeria142 participantsStarted 2020-01-02

Plain-language summary

The study will be carried out by the principal investigator and his team at the Division of Cardiovascular and Thoracic Surgery of the Department of Surgery, College of Medicine, University of Ibadan and the University College Hospital, Ibadan (UCH), which is the Teaching Hospital of the Medical College.The study sets out to prospectively compare the early and long-term outcomes between the use of purse-string (suturing U-technique) and Un-reapproximated thoracostomy wound edges (Occlusive adhesive-absorbent dressing application) at the time of removal of thoracostomy tube drain in patients who have had chest tube insertion.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Pleural effusion
✓. Traumatic or spontaneous pneumothorax
✓. Traumatic haemothorax
✓. As an adjunct to a thoracotomy for a non-neoplastic and or non -infective condition

Exclusion criteria

✕. An associated pyopneumothorax
✕. Cancer encuirasse of the chest wall
✕. Unconscious with unclear consent situation
✕. With infective or neoplastic conditions of the chest wall
✕. With individual or family history of wound failure e.g. unsightly scars
✕. Who has had irradiation of the chest or chemotherapy administration within 6 weeks from the time of requirement of the chest tube insertion
✕. Who is at risk of immunosuppression i.e. diabetes, HIV infection, on steroid therapy, ongoing chemotherapy or who has a congenital or any other acquired immune deficiency state

What they're measuring

Number of participants with Proportion of clinical and wound complications with indwelling chest tube - SEVERE PAIN

Timeframe: It will span the period from chest tube insertion till chest tube removal

Number of participants with clinical and wound complications with indwelling chest tube- TUBE DISLODGEMENT

Timeframe: It will span the period from chest tube insertion till chest tube removal

Number of participants with clinical and wound complications with indwelling chest tube - PERITUBAL LEAKAGE

Timeframe: It will span the period from chest tube insertion till chest tube removal

Number of participants with early wound complications after chest tube removal- AIR SUCK-IN

Timeframe: It will span the period from chest tube removal till the patient is discharged home after chest tube removal

Number of participants with early wound complications after chest tube removal- POST-INSERTION WOUND INFECTION

Timeframe: It will span the period from chest tube removal till the patient is discharged home after chest tube removal

Number of participants with early wound complications after chest tube removal- WOUND DEHISCENCE

Timeframe: It will span the period from chest tube removal till the patient is discharged home after chest tube removal

Trial details

NCT IDNCT04193241

SponsorUniversity of Ibadan

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2020-12-31

Contact for this trial

Lateef A Baiyewu, MD,FWACS

+234 80 34455695 bayan_latyph@yahoo.com

View on ClinicalTrials.gov More Pleural Effusion trials

Plain-language summary

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Pleural effusion
✓. Traumatic or spontaneous pneumothorax
✓. Traumatic haemothorax
✓. As an adjunct to a thoracotomy for a non-neoplastic and or non -infective condition

Exclusion criteria

✕. An associated pyopneumothorax
✕. Cancer encuirasse of the chest wall
✕. Unconscious with unclear consent situation
✕. With infective or neoplastic conditions of the chest wall
✕. With individual or family history of wound failure e.g. unsightly scars
✕. Who has had irradiation of the chest or chemotherapy administration within 6 weeks from the time of requirement of the chest tube insertion
✕. Who is at risk of immunosuppression i.e. diabetes, HIV infection, on steroid therapy, ongoing chemotherapy or who has a congenital or any other acquired immune deficiency state